This emerging biotech company is taking an innovative approach to DEFEATING VIRUSES, including COVID-19!

With time and the emergence of new and deadly viruses, this company could become a DOMINANT leader in nanomedicine and antiviral therapy!

NanoViricides, Inc. (U.S. - NNBV) has been developing nanomedicine drugs against viruses for over 15+ years and their most recent developments could prove to be market disrupting and world-changing.

Download Research Report

Learn more about NanoViricides, Inc.  by gaining access to the latest research report

    Thanks for subscribing!
    Check your email for a confirmation message.

    NanoViricides, Inc. is a client of Tradigital IR, an investor relations and communications firm. Please see our disclosures in the research report as well as on our website

    With their invention of nanoviricide® technology that defines a novel mechanism enabling first-in class drugs against viruses, NanoViricides, Inc. has become a global leader in the antiviral therapy and nanomedicine space.


    Especially with the most recent news…

    NanoViricides, Inc.’s most recent developments directly target and fight against SARS-CoV-2!    

    These developments anti-COVID treatments could head straight to the market soon!

    Since the company's recent process completion of licensing the human Coronavirus field for drug development and commercialization, NanoViricides, Inc. has rapidly advanced through the clinical trial process - leading the company inches away from testing their drug candidates to treat SARS-CoV-2 in human clinical trials. 

    One of Nanoviricides, Inc.’s drug candidates has been produced and tested in the form of oral gummies - setting up the company to aid COVID-19 positive patients, including those (children and older patients) who need more accessible treatments. 

    With effective and satisfactory solutions to battling against the pandemic, NanoViricides', Inc. official entrance into the antiviral therapy and nanomedicine market may capture high demand for proactive antiviral means to prevent new outbreaks of COVID-10 among other viral infections including HIV, Shingles, Ebola, and more.


    • Once NanoViricides' drug products hit the market - it may change the world!
    • Over 15+ years of experience in nanomedicine and antiviral therapy developments 
    • Current fast moving drug candidate developments and indications for treatment of SARS-CoV-2 patients 
    • Possession of a strong, diverse, and promising product pipeline that addresses the world’s most infamous and infectious viruses 
    • Antiviral therapy and nanomedicine market is expected to experience exponential growth by 2026
    • NanoViricides, Inc.’s developments are sustainable beyond the COVID-19 as its diverse product pipeline targets several markets simultaneously: 
    • NanoViricides, Inc.’s developments are sustainable beyond the COVID-19 as its diverse product pipeline targets several markets simultaneously: 
      • The global HIV drugs market is projected to grow from $30.46 billion in 2021 to $45.58 billion in 2028 at a CAGR of 5.9% in forecast period, 2021-2028.
      • The global influenza medication market size stood at USD 889.2 million in 2018 and is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period.
      • The shingles treatment market is expected to witness a high growth over the forecast period owing to the increasing prevalence of shingles .The global Shingles Treatments market is valued at million USD in 2017 and is expected to reach million USD by the end of 2023, growing at a CAGR of between 2017 and 2023.
    • SEC and Exchange Commission (SEC) on October 12, 2021 reported an increase of cash and cash equivalent current assets balance to approximately $20.8 Million, $9.08 Million in Property and Equipment (P&E) assets. Total Current liabilities were less than $0.4 million.
    • Strong P&E assets comprise their cGMP-capable manufacturing and R&D facility.

    Led by inventor of nanoviricides technology: President, Dr. Anil Diwan and managed by a highly effective team with decades of entrepreneurial, pharmaceutical, and nanomedicine experience.


    Antibodies have been developed as drugs against viruses. However, each antibody only binds by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sickness. 

    Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates. 

    While Moderna and Pfizer recently distributed their new development of the COVID-19 vaccines, NanoViricides, Inc.  is taking a more innovative approach beyond antibodies and vaccines.

    See Below for Nanoviricides' Unique, Novel, Post-Immunotherapeutic “Bind-Encapsulate-Destroy” Mechanism

    NanoViricides, Inc. is a development stage company with a unique nanomedicine technology. The company is developing nanotechnology-based biomimetic anti-viral medicines, called “nanoviricides.” 

    In contrast to immunizations, A nanoviricide is a Nanomachine that completes the task of destroying a virus WITHOUT the help of the patient’s immune system.

    This solves the key issues of drug resistance from viral mutations as nanoviricides drugs are empowered by biomimetic technology.

    Designed by NanoViricides to “fool” a virus, the nanoviricides attach to the agent in the same way that the virus normally attaches to receptors on a cell surface. 

    The nanoviricide dismantles and eliminates the virus’ effect on the host by directly attacking the virus at multiple points.


    NanoViricides, Inc. is diligently developing AN ACCESSIBLE, SAFE, and DIVERSE catalog of products.

    With NanoViricides, Inc. broad pipeline, the company is enabled by the proprietary and unique post-immunotherapeutic "bind-encapsulate-destroy" technology platform, well-positioning the Company to be an overall therapeutic leader across the anti-viral ecosystem. (click here to read more)

    NanoViricides, Inc. has already demonstrated its leadership within the antiviral therapeutic space by developing a diverse and promising product pipeline that attacks viral infections from ALL ANGLES. 

    From Herpes and Ebola to Shingles and several severe influenzas, NanoViricides, Inc. currently has multiple drug candidates in development to treat various viruses through various means such as topical creams, eye drops, injections, and gummies. 

    NanoViricides’ promising developments of these diverse products are projected to meet the individual and personalized needs of patients through these EFFECTIVE and ACCESSIBLE treatments.

    Some of these indications include BOTH injectable and ORAL influenced drugs that are expected to be effective REGARDLESS of mutations. 


    NanoViricides, Inc.’s promising pipeline is targeting a multi-billion antiviral therapy market.

    With the antiviral area currently in the spotlight due to the search for effective COVID-19 treatments , the global anti therapy market is valued for $48.1 million in 2018 and is estimated to garner $79.8 million by 2026, rising at a CAGR of 6.7% from 2019 to 2026. 

    The extensive growth of the antiviral therapy market is mainly attributed to the increasing prevalence of human immunodeficiency viruses (HIV) infections and hepatitis C, which NanoViricides is actively pursuing in addition to COVID-19. 

    NanoViricides, Inc. current programs for HIV, Dengue, Ebola/ Marburg and other viruses comprise a market size of $40~70 Billion. 

    Additionally, NanoViricides HerpeCide™ Program has its first drug candidate for treatment of shingles, NV-HHV-101, within a topical cream. 

    The market size for this program is more than ~$10Bn, with the market size for NV-HHV-101 estimated at between $0.5Bn~$2Bn by independent market studies.


    As COVID-19 continues to spread across the globe, increased demand for nanomedicine has led to the strong growth of the global nanomedicine market. 

    Looking forward, the market is projected to grow at a CAGR of 10% during 2021-2026.

    Extensive research, contributed by NanoViricides, Inc., and development (R&D) activities in the field of biotechnology have anticipated to drive the market toward growth. 

    Research shows that nanomedicine is HIGHLY beneficial in the treatment of immunological and infectious disease.


    NanoViricides, Inc. programs address large markets within the antiviral space that could result in treatment-transformations and market size explosions.

    Using the nanoviricides® platform technology, NanoViricides, Inc. has developed drug candidates that target a fruitful and expansive market as the company attacks the world’s most pervasive viruses.

    With anticipated market explosion on the horizon, NanoVericide’s anti-Herpes drugs franchise, FluCide franchise, and other pipeline products will reap the benefits of this market boom. 

    Setting its sights on expanding its current portfolio with COVID-19 drug candidates, NanoViricides has already established itself as a transformative leader in the antiviral market. 


    Creator and developer of nanomedicine technologies, Dr. Anil R. Diwan co-founded NanoViricides and currently serves as the company’s President and Executive Chairman.

    Diwan has over 45+ years of experience in entrepreneurship and bio-pharmaceutical R&D. Beginning with the invention of novel polymeric micelle-based nanomedicine technologies in 1991, it wasn’t until 2005 that NanoViricides, Inc. was born.

    Since Dr. Diwan’s efforts for the company’s 2013 up listing from the OTC Markets to NYSE-American, Dr. Diwan has led several of the finance efforts since 2010 and has raised over 60+ MM in equity financing. 

    Under Dr. Diwan’s leadership, Nanoviricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels, resulting in expanding the drug pipeline every day.

    He has won several NIH SBIR (Small business innovation research) grant awards and holds a Ph.D. from Rice University, Tx, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. 

    He has over 60 patents issued internationally resulting from three fundamental international patent applications. 

    Download the NNVC Research Report to learn more about NanoViricides, Inc.


    NanoViricides, Inc. is a client of Tradigital IR, an investor relations and communications firm. Please see our disclosures in the research report as well as on our website


    NanoViricides, Inc. (NYSE: NNVC) is set to be a market disruptor in antiviral therapy and nanomedicine as it is on its way to successfully capturing a $80 B market with its cutting-edge nanoviricide® technology and drug products.

    With its ongoing expansion and development of their diverse and promising product pipeline, NanoViricides, Inc. (NYSE: NNVC) is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space. 

    The Bottom Line

    Upon these developments, consumers are projected to accept these drug products as they will offer greater personalization and accessibility to combating and eradicating viral infections. 

    There is no denying that the world is changing… viruses are becoming more rampant and being ahead of the problem makes NNVC an emerging NYSE company that could see unstoppable growth ahead!

    NanoViricides, Inc.’s, infrastructure, responsivity to health crisis, highly effective management team, and extensive experience should place this company at the top of your watch list! 

    Advancements within the nanomedicine and antiviral therapy market are just around the corner and NNVC may be the first to enter through the door. 

    Start your research today!
    Download Report

    NanoViricides, Inc. is a client of Tradigital IR, an investor relations and communications firm. Please see our disclosures in the research report as well as on our website



    TraDigital IR is a publisher. You understand and agree that no content published on this site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is..

    In exchange for publishing services rendered by TraDigital IR on behalf of the client named herein, including the promotion by said company in any content on this site, TraDigital IR received compensation for such.

    This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only.   never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not  registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. By viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.  in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and nanoviricides, inc. tradigital was hired for a period beginning august 2019 and ending november 2019 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned sixty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 02/13/2020. We sold this entire position as of 3/4/2022.  tradigital was hired for a period beginning january 2020 and ending january 2021 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned fifty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 06/02/2020. We sold this entire position as of 3/4/2022. tradigital was hired to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid twenty-five thousand usd, via ach in february 2022 and the marketing will last for thirty days. We do not own any shares of nanoviricides, inc.  Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra.